The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

Joseph A. Jakubowski, David Erlinge, Dimitrios Alexopoulos, David S. Small, Kenneth J. Winters, Paul A. Gurbel, Dominick J. Angiolillo

Research output: Contribution to journalArticle

Abstract

Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalAmerican Journal of Cardiovascular Drugs
DOIs
StateAccepted/In press - Nov 17 2016

Fingerprint

Clinical Pharmacology
Purinergic P2Y Receptor Antagonists
Blood Platelets
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Population
Aspirin
Prasugrel Hydrochloride
Pharmacokinetics
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Jakubowski, J. A., Erlinge, D., Alexopoulos, D., Small, D. S., Winters, K. J., Gurbel, P. A., & Angiolillo, D. J. (Accepted/In press). The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. American Journal of Cardiovascular Drugs, 1-13. https://doi.org/10.1007/s40256-016-0202-3

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. / Jakubowski, Joseph A.; Erlinge, David; Alexopoulos, Dimitrios; Small, David S.; Winters, Kenneth J.; Gurbel, Paul A.; Angiolillo, Dominick J.

In: American Journal of Cardiovascular Drugs, 17.11.2016, p. 1-13.

Research output: Contribution to journalArticle

Jakubowski, JA, Erlinge, D, Alexopoulos, D, Small, DS, Winters, KJ, Gurbel, PA & Angiolillo, DJ 2016, 'The Rationale for and Clinical Pharmacology of Prasugrel 5 mg', American Journal of Cardiovascular Drugs, pp. 1-13. https://doi.org/10.1007/s40256-016-0202-3
Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA et al. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. American Journal of Cardiovascular Drugs. 2016 Nov 17;1-13. https://doi.org/10.1007/s40256-016-0202-3
Jakubowski, Joseph A. ; Erlinge, David ; Alexopoulos, Dimitrios ; Small, David S. ; Winters, Kenneth J. ; Gurbel, Paul A. ; Angiolillo, Dominick J. / The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. In: American Journal of Cardiovascular Drugs. 2016 ; pp. 1-13.
@article{a3568d54d33e4d0bb31a132f64b9c34d,
title = "The Rationale for and Clinical Pharmacology of Prasugrel 5 mg",
abstract = "Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.",
author = "Jakubowski, {Joseph A.} and David Erlinge and Dimitrios Alexopoulos and Small, {David S.} and Winters, {Kenneth J.} and Gurbel, {Paul A.} and Angiolillo, {Dominick J.}",
year = "2016",
month = "11",
day = "17",
doi = "10.1007/s40256-016-0202-3",
language = "English (US)",
pages = "1--13",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

AU - Jakubowski, Joseph A.

AU - Erlinge, David

AU - Alexopoulos, Dimitrios

AU - Small, David S.

AU - Winters, Kenneth J.

AU - Gurbel, Paul A.

AU - Angiolillo, Dominick J.

PY - 2016/11/17

Y1 - 2016/11/17

N2 - Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.

AB - Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.

UR - http://www.scopus.com/inward/record.url?scp=84995478815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995478815&partnerID=8YFLogxK

U2 - 10.1007/s40256-016-0202-3

DO - 10.1007/s40256-016-0202-3

M3 - Article

C2 - 27854064

AN - SCOPUS:84995478815

SP - 1

EP - 13

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

ER -